Biogen (NASDAQ:BIIB) Releases FY24 Earnings Guidance

Biogen (NASDAQ:BIIB) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $16.10-16.60 for the period, compared to the consensus estimate of $16.17. Biogen also updated its FY 2024 guidance to 16.100-16.600 EPS.

Biogen Stock Performance

BIIB stock traded down $0.21 during trading on Friday, hitting $173.79. 1,456,042 shares of the company traded hands, compared to its average volume of 1,134,143. The stock’s 50-day simple moving average is $192.71 and its 200 day simple moving average is $209.37. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 1.48. The company has a market cap of $25.31 billion, a PE ratio of 15.70, a P/E/G ratio of 1.82 and a beta of -0.06. Biogen has a 1 year low of $173.14 and a 1 year high of $268.30.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $4.08 EPS for the quarter, beating analysts’ consensus estimates of $3.77 by $0.31. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.43 billion. Biogen had a return on equity of 14.98% and a net margin of 16.81%. The business’s revenue was down 2.5% compared to the same quarter last year. During the same period in the previous year, the business earned $4.36 earnings per share. On average, equities analysts expect that Biogen will post 16.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BIIB has been the subject of several research reports. Morgan Stanley cut Biogen from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $285.00 to $204.00 in a research report on Thursday. TD Cowen dropped their price target on Biogen from $300.00 to $275.00 and set a “buy” rating for the company in a research report on Thursday. Robert W. Baird dropped their price target on Biogen from $316.00 to $294.00 and set an “outperform” rating for the company in a research report on Monday, July 29th. UBS Group lowered their price objective on Biogen from $234.00 to $202.00 and set a “neutral” rating on the stock in a research note on Thursday, October 3rd. Finally, Needham & Company LLC reissued a “buy” rating and set a $270.00 price objective on shares of Biogen in a research note on Wednesday. Ten equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $262.83.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 431 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $204.22, for a total transaction of $88,018.82. Following the sale, the insider now owns 5,316 shares in the company, valued at $1,085,633.52. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by company insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.